FDA rejects Replimune's melanoma therapy despite breakthrough designation, raising urgent questions about regulatory ...
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (OKYO) (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat ...
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio ...
Against the backdrop of ongoing transformation in the global pharmaceutical industry, policy factors are increasingly becoming a core variable shaping the development of innovative drugs. From reforms ...
The MarketWatch News Department was not involved in the creation of this content. Prevention of Renarcotization after Rescue from Opioid Overdose is a New Indication and Planned Clinical Studies will ...
Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway into the Clinic Onchilles Pharma, a private biotech company ...
Pathways Neuro Pharma Inc. is committed to pushing the boundaries of neuroscientific research and addressing unmet medical needs in neurological disorders. Dr. Thompson's unparalleled experience, ...
In chemical processes for producing pharmaceuticals, catalysts are a core technology that determines production speed and ...
Prevention of Renarcotization after Rescue from Opioid Overdose is a New Indication and Planned Clinical Studies will be Supported by Pioneering a First-of-Its-Kind, Capital Efficient, Modeling and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results